|
Drug-price reforms need not affect research on rare diseases – or the Canadians who have them
Monday, August 26th, 2019
Pricing on these drugs is not subject to market forces in that even as competition comes into the market, the drug prices do not fall… We hope that patients, advocacy groups and physicians continue to collaborate with manufacturers and regulatory agencies on… strategies that attempt to bring more transparency and value for health-related outcomes into drug-pricing models.
Tags: Health, jurisdiction, mental Health, pharmaceutical
Posted in Health Debates | No Comments »
Recent Comments